MDS 2021 | Novel therapies in low-risk MDS
Valeria Santini
• 22 Sep 2021
Valeria Santini, MD, University of Florence, Florence, Italy, outlines the novel therapies for the treatment of low-risk myelodysplastic syndromes (MDS), highlighting clinical data from key trials. Specifically discussed is luspatercept, a fusion ligand trap agent for activin II receptor and B, imetelstat, a first-in-class oligonucleotide and roxadustat, a potent and reversible orally bioavailable small-molecule inhibitor of HIF-PH enzymes. This interview took place at the 16th International Congress on Myelodysplastic Syndromes, held virtually in 2021.
